We will be comparing the differences between Charles River Laboratories International Inc. (NYSE:CRL) and Agilent Technologies Inc. (NYSE:A) as far as institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation are concerned. The two businesses are rivals in the Medical Laboratories & Research industry.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Charles River Laboratories International Inc.||2.38B||2.69||227.35M||4.52||29.15|
|Agilent Technologies Inc.||5.02B||4.41||1.12B||3.59||18.86|
Table 1 demonstrates Charles River Laboratories International Inc. and Agilent Technologies Inc.’s top-line revenue, earnings per share (EPS) and valuation. Agilent Technologies Inc. is observed to has lower earnings, but higher revenue than Charles River Laboratories International Inc. The company with the higher price-to-earnings out of the two companies is considered for more expensive of the two firms currently. Charles River Laboratories International Inc.’s shares have been trading at higher price-to-earnings ratio which means it is currently more expensive than Agilent Technologies Inc.
Table 2 demonstrates the return on assets, net margins and return on equity of Charles River Laboratories International Inc. and Agilent Technologies Inc.
|Net Margins||Return on Equity||Return on Assets|
|Charles River Laboratories International Inc.||9.55%||17.8%||5.9%|
|Agilent Technologies Inc.||22.31%||24.3%||13.2%|
Risk and Volatility
A 1 beta means Charles River Laboratories International Inc.’s volatility is 0.00% less than Standard & Poor’s 500’s volatility. Competitively, Agilent Technologies Inc.’s beta is 1.34 which is 34.00% more volatile than Standard & Poor’s 500.
Charles River Laboratories International Inc.’s Current Ratio and Quick Ratio are 1.6 and 1.4 respectively. The Current Ratio and Quick Ratio of its competitor Agilent Technologies Inc. are 3.4 and 2.8 respectively. Agilent Technologies Inc. therefore has a better chance of paying off short and long-term obligations compared to Charles River Laboratories International Inc.
On the other side Agilent Technologies Inc. pays an annual dividend of $0.63 per share. It’s dividend yield is 0.89%. No dividend is paid out by Charles River Laboratories International Inc.
The next table highlights the given recommendations and ratings for Charles River Laboratories International Inc. and Agilent Technologies Inc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Charles River Laboratories International Inc.||0||1||3||2.75|
|Agilent Technologies Inc.||0||0||8||3.00|
Charles River Laboratories International Inc. has a consensus price target of $157, and a 19.56% upside potential. Competitively Agilent Technologies Inc. has a consensus price target of $87.56, with potential upside of 24.93%. The data from earlier shows that analysts view suggest that Agilent Technologies Inc. seems more appealing than Charles River Laboratories International Inc.
Insider and Institutional Ownership
Institutional investors held 95.5% of Charles River Laboratories International Inc. shares and 88.5% of Agilent Technologies Inc. shares. Charles River Laboratories International Inc.’s share held by insiders are 1.4%. Comparatively, 0.4% are Agilent Technologies Inc.’s share held by insiders.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Charles River Laboratories International Inc.||-3.41%||-8.11%||-5.38%||-3.53%||22.66%||16.3%|
|Agilent Technologies Inc.||-11.71%||-15.87%||-12.44%||0.55%||-2.27%||0.27%|
For the past year Charles River Laboratories International Inc.’s stock price has bigger growth than Agilent Technologies Inc.
Agilent Technologies Inc. beats Charles River Laboratories International Inc. on 12 of the 16 factors.
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery and development services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening preclinical drug candidates comprising genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for identification of a druggable target through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, which comprise bioanalysis, pharmacokinetics, drug metabolism, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. This segment also offers specialized testing of biologics and devices that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs and chickens used in the manufacture of live viruses. The company serves pharmaceutical and biotechnology companies, contract research organizations, agricultural and chemical companies, life science and veterinary medicine companies, contract manufacturing organizations, medical device companies, diagnostic and other commercial entities, hospitals, academic institutions, and government agencies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. Its Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; laboratory software and informatics systems; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The companyÂ’s Diagnostics and Genomics segment provides reagents, instruments, software, and consumables; arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment services; and equipment focused on production of synthesized oligonucleotides for use as active pharmaceutical ingredients. Its Agilent CrossLab segment offers GC and LC columns, sample preparation products, custom chemistries, and various laboratory instrument supplies; and startup, operational, training, and compliance support, as well as asset management and consultation services. The company markets and sells its products through direct sales, electronic commerce, resellers, manufacturers' representatives, and distributors. It has a collaboration agreement with University of Leuven to focus on detecting genetic abnormalities in cell-free DNA and embryo biopsies. Agilent Technologies, Inc. was founded in 1999 and is headquartered in Santa Clara, California.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.